CAMBRIDGE, Mass. & NEW YORK--(BUSINESS WIRE)--GNS Healthcare (GNS), a leading provider of big data analytics in health care, announced today that CHDI Foundation, Inc. (CHDI), a privately-funded, nonprofit biomedical research organization exclusively dedicated to Huntington’s disease, has committed to continuing their collaboration to accelerate the discovery process for therapeutics that will slow the progression of Huntington’s disease.
The multi-year project leverages best-in-class genomic data and computational modeling and a committed team of accomplished scientists from CHDI and GNS, who are collaborating to discover the most promising genetic and molecular targets for Huntington’s disease drug development. GNS will apply its patented inference engine and machine-learning technology, REFS™, to the enormous CHDI dataset, which encompasses genomic, molecular, phenotypic, and other data characterizing manifestation of Huntington’s disease, in humans and in multiple mouse models of the disease.
Help employers find you! Check out all the jobs and post your resume.
